• Korean Journal of Psychosomatic Medicine
• /
• v.5 no.1
• /
• pp.89-96
• /
• 1997

This study was designed to determine whether cognitive impairment was evident in patients with SLE. Also, it aimed to examine the association of cognitive impairment with other clinical variables. The subjects consisted of 20 patients with mildly active SLE and 20 healthy controls. Methods : A total of 20 SLE patients and 20 normal controls completed a computerized neuropsychological test battery using Vienna Test System. These included Cognitrone test, Continuous attention test, Corsi block tapping test, Standard progressive matrices. Also, neuro-behavioral cognitive status examination was done. The symptom severity of depression was measured with Beck Depression Inventory, Hamilton Depression Rating Scale, and current medications were documented. Disease activity was rated using the SLE diasease activity index (SLEDAI). Results : SLE patients had poorer performance than normal controls on the tests of Cognitrone, attention, nonverbal IQ and memory, independent of age, education, disease activity, steroid use and depression status. Conclusion : Cognitive dysfunction was not uncommon in ambulatory SLE patients as measured by standardized neuropsychological tests. It seemed to occur independently of various clinical variables. These findings would suggest that cognitive dysfunction in SLE may be explained by reflecting subclinical central nervous system(CNS) involvement, rather than coexisting psychological distress due to chronic illness or side effect of medication.

• Journal of The Korean Association For Science Education
• /
• v.18 no.4
• /
• pp.503-516
• /
• 1998

The purpose of the present study was to evaluate some variables, such as learner's cognitive characteristics and a training-program emphasized proportional logic, in proportional reasoning development. Seven hundred and ninety students in junior high schools were enrolled as subjects for the study which investigated learner's cognitive characteristics in proportional reasoning development and asked to perform tests of logical thinking, card sorting, planning, mental capacity, cognitive style, brain lateralization, information processing pattern and scientific reasoning. In addition, one hundred and thirty-three students who failed to solve proportional thinking items were administered a training program which has been applied to improve the subjects' proportional reasoning skills. The results showed a significant higher correlation between subjects' performance score on proportional thinking test, and their age and scores on scientific reasoning test, mental capacity, information processing test and perseveration errors on card sorting test. Also, the training program applied in this study showed an effective result in developing subjects' proportional reasoning skills. Further, this study may serve as a suggestion in the efforts to investigate factors of proportional thinking development and a contribution for the future research in other logical thinking development.

• Korean Journal of Psychosomatic Medicine
• /
• v.30 no.2
• /
• pp.112-118
• /
• 2022

Objectives : Zolpidem is a common drug used in insomnia. However, there are several reports of side effects of the central nervous system or sleep related behavior in patients who took zolpidem. This study was conducted to investigate risk factors affecting sleep related behavior after taking zolpidem in inpatients. Methods : From January 1, 2019 to December 31, 2019, medical records of patients who took zolpidem hospitalized at Inha University Hospital were reviewed retrospectively. Results : 907 patients who took Zolpidem, 102 (11.2%) showed sleep related behavior, and if they were 65 years of age or older, men, taking antipsychotics, and taking antipsychotics and benzodiazepines at the same time, they were significantly more likely to show sleep related behavior. Conclusions : Risk factors for sleep-related behavior after use of zolpidem are estimated gender, elderly, antipsychotics, and combination of antipsychotics and benzodiazepines.

• Korean Journal of Biological Psychiatry
• /
• v.1 no.1
• /
• pp.117-123
• /
• 1994

This study was performed to examine the role of neuroleptics may in the development of neurologic soft signs in patients with schizophrenia. Neurologic soft signs were evaluated in 28 neuroleptic naive patients with schizophrenia or schizophreniform disorder and 31 neuroleptic non-naive patients with schizophrenia using a structured tool for measuring neurologic abnormalities, Neurological Evaluation Scale-Korean version(NES-K). Relationship to dose, duration and neurological side effects of neuroleptic treatment were also evaluated. Total scores of NES-K in neuroleptic naive group were significantly higher than those of non-naive group. Scores of motor coordination, sequencing of complex motor acts and others items in functional subcategories were also significantly higher in drug-naive patients. The sensory integration item was not different between two groups. After controlling covariates such ac dose of neuroleptics, age and sex, total scores, motor coordination and others items of NES-K were significantly higher in neuroleptic naive group. However there was no difference between drug naive and non-naive group in the sequencing of complex motor acts item due to effects of these covariates. In neuroleptic non-naive group the dosage of neuroleptics correlated with the motor coordination item, nor were there relationships between duration and side effects of neuroleptic treatment and neurologic soft signs. These findings suggest that neuroleptic treatment may play a only relative role in the development of neurologic soft signs in patients with schizophrenia and these abnormalities may be one of possible trait markers of schizophrenia. To elucidate this opinion, well-controlled, prospective study in same subjects will be helpful.

• Korean Journal of Biological Psychiatry
• /
• v.14 no.2
• /
• pp.91-98
• /
• 2007

Objectives : Considering the impact of depressive illness on physical and mental health of both mother and fetus, specification of a treatment algorithm for depressive disorder during pregnancy is legitimated. This article provides a systemic review of treatments for depressive disorder during pregnancy and lactation. Methods : According to the search strategy of the Clinical Research Center for Depression of Korean Health 21 R & D Project, PubMed and EMBASE were searched using terms with regard to the treatment of depressive disorders during pregnancy and lactation. Reference lists of related reviews and studies were searched. In addition, relevant practice guidelines were searched using the PubMed. All identified clinical literatures were reviewed and summarized in a narrative manner. Results : Pharmacotherapy during pregnancy and lactation requires a comprehensive assessment of the risks and benefits of treatment for both mother and fetus or neonate. Recently, there is growing evidence that the use of tricyclic and selective serotonin reuptake inhibitors during pregnancy and lactation does not result in increased risks of teratogenicity. Treatment strategies are described according to the point of time of pregnancy or lactation. FDA categories for antidepressants during pregnancy and lactation are described. In addition, issues regarding to the electroconvulsive therapy and psychosocial treatment are discussed. Conclusion : The treatment option for depressive disorders during pregnancy and lactation depends on the severity of depressive illnesses of the individual patient. For mild to moderate depression, the non-pharmacological treatment should be considered first. For moderate to severe depression, pharmacotherapy should be administered in addition to the psychosocial treatment. ECT is recommended for depressive disorder of severe intensity. As the research knowledge is limited, the recommendations should based on the best judgement of psychiatrists.

• Journal of the Korean Academy of Child and Adolescent Psychiatry
• /
• v.16 no.2
• /
• pp.219-230
• /
• 2005

Objectives : This study was designed to compare the demographic data, clinical characteristics, developmental delay, and psychological tests between childhood-onset and adolescent-onset schizophrenic in-patients. Methods Medical records of the 17 childhood-onset (very early onset) Schizophrenia and 16 adolescent-onset (early onset) Schizophrenia in-patients were reviewed. Sex, age, psychiatric past history, prodromal symptoms and period, subtype, co-morbid disease, developmental delay, prescribed drug and dosage, treatment response, intelligence quotient (IQ), and Rorschach test were evaluated. Results : The mean admission age of childhood-onset (very early onset) group and adolescent-onset (early onset) group were 12.69$({\pm}2.34)$ and 15.13$({\pm}1.04)$ years. The mean onset age of childhood-onset(very early onset) group and adolescent-onset (early onset) group were 10.79$({\pm}1.95)$ and 14.46$({\pm}0.82)$ years. The mean prodromal period of childhood-onset (very early onset) group and adolescent-onset (early onset) group were 15.94$({\pm}12.33)$ and 8.06$({\pm}6.10)$ month. The time to remission period of childhood-onset (very early onset) group and adolescent-onset (early onset) group were 50.58$({\pm}24.67)$ and 30.06$({\pm}18.04)$ days. Longer time to remission period in childhood-osnet (very early onset) group was associated with earlier age of onset. The mean of total IQ, performance IQ, verbal IQ were at an average level. Discussion : Childhood-onset (very early onset) group and adolescent-onset (early onset) group Schizophrenia had different clinical and psychological features including prodromal period, and IQ subtests.

• Korean Journal of Biological Psychiatry
• /
• v.11 no.1
• /
• pp.61-63
• /
• 2004

We describe the case of a 73 year-old female patient, YSG, who initially presented with a manic episode without any previous psychiatric history and was later diagnosed as having a meningioma in the left frontal lobe. YSG's symptoms were characterized by hyperactivity, insomnia, aggressive behavior with an auditory hallucination. She showed no abnormal signs on a complete neurologic examination. A gadolinium-enhanced MRI study showed a huge, extra-axial mass with homogenous enhancement in the left high convexity of the frontal lobe. Her manic symptoms subsided after administration of risperidone 1mg and valproic acid 500mg daily, for three weeks without surgical resection of the tumor. These findings suggest that YSG's mania might have resulted from the left-sided frontal tumor, and that her symptoms were treated rapidly by small doses of risperidone combined with valproic acid. Medical staff who care for manic patients should be aware of this possibility of a organic lesion without evidence of neurologic disease.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1993.04a
• /
• pp.93-93
• /
• 1993

도파민 D 수용체 및 5-HT 수용체 차단기전을 지닌 새로운 항정신분열증 약물인 risperidone은 활성형 대사물로 9-OH risperidone을 체내에서 생성하는 바, 이 대사과정의 유전적 다형성의 여부 즉 hydroxylation 과정에 CYPIID6의 관여 여부를 검토코자 하였다. Metoprolol 100 mg 경구투여로 CYPIID6의 대사능의 표현형을 결정한 12명의 정상 피험자(11명: extensive metabolizer, 1명: poor metabolizer)를 대상으로 하였으며, 피험자는 risperidone 1 또는 2 mg 경구투여후 혈중 risperidone 및 9-OH risperidone 농도를 경시적으로 radioimmunoassay법으로 측정하였다. 이들 피험자중 6명의 extensive metabolizer는 quinidine 600 mg/day의 용량 투여로 CYPIID6의 활성도를 완전 억제시킨 후 risperidone 1 mg 경구투여에 따른 약동학적 성상을 재검토하여 risperidone hydroxylation에 CYPIID6의 관여 여부를 검토하였다. 1) 1명의 poor metabolizer는 extensive metabolizer에 비해 현저히 긴 risperidone 반감기를 보였다. 2) 12명의 피험자에서 관찰된 metoprolol metabolic ratio는 risperidone 혈장 반감기 및 log(risperidone AUC/9-OH-risperidone AUC)와 유의한 상관성을 나타내었다. 3) Quinidine 투여는 risperidone의 반감기의 유의한 증가와 9OH risperidone AUC의 현저한 감소를 보였으나, 9-hydroxylation 대사과정이 완전히 억제되지는 않았다.

• Korean Journal of Psychosomatic Medicine
• /
• v.22 no.2
• /
• pp.138-142
• /
• 2014

Burning mouth syndrome is characterized by intra-oral burning sensation without any organic abnormalities. This syndrome is associated with various etiological factors such as neuropathy, malnutrition, menopause and depression. Several medications have been tried for the treatment. Those are analgesics, hormones, anticonvulsants and antidepressants. However, optimal effective pharmacologic treatment remains still unknown. The purpose of this case study is to report the clinical effectiveness of gabapentin in the treatment of burning mouth syndrome in postmenopausal women with comorbid depression. We report two menopausal women. Antidepressants were effective for improving depressive symptoms, but it had no effects on intra-oral burning sensation. Gabapentin reduced intra-oral burning sensation effectively for all two patients. One patient reported 55% reduction(a decrease from 9 to 4 on VAS), the other patient reported 35% reduction(from 8 to 5) of the intra-oral burning sensation during 16 weeks. The minimal effective daily dose of gabapentin was 300mg. This study suggests that gabapentin might be a useful, effective therapeutic option for treating burning mouth syndrome in postmenopausal women with comorbid depression. Further prospective clinical studies are needed to investigate the effectiveness of gabapentin in patients with burning mouth syndrome.

• Proceedings of the Korean Institute of Industrial Safety Conference
• /
• 1997.11a
• /
• pp.267-270
• /
• 1997

악취 물질은 주로 정유공장, 분뇨 처리장, 축산$\cdot$수산 가공업, 화학공장 등에서 발생하며 작업장 내의 직원 뿐만 아니라 인근 지역주민들에게 정신적인 불쾌감을 주는 동시에 인체에 매우 유해한 물질들이다. 이들 악취의 주성분은 메틸머켑탄, 황화수소, 암모니아, 트리메틸아민 등의 물질이다. 이들 물질의 제거 방법에는 약액세정법, 직접연소법, 활성탄흡착법 등이 있다. 이중 활성탄 홉착법은 설비비와 운영경비상의 잇점으로 오랫동안 사용되어져 왔고, 현재도 악취가 많이 발생하는 사업장의 악취 제거 방법으로 널리 사용되고 있다. 그러나 기존의 활성탄을 이용한 흡착제거는 처리효율이 낮고, 이에 따른 흡착제의 충진량이 많아지고 시설용량이 커지는 등의 결점이 있다. 이러한 문제점을 해결하기 위해 활성탄의 성질의 개선과 ACF와 같은 흡착제의 활용등에 대한 연구들이 진행되고 있다. (중략)